Skip to main content
Premium Trial:

Request an Annual Quote

Heikki Lanckriet, Pilar de la Huerta, Peter Llewellyn-Davis

Sygnis has announced changes to its management team and supervisory board. Former Co-CEO Heikki Lanckriet will become sole CEO of the company and will also retain his role as CSO. Additionally, supervisory board members Maria-Hesús Sabatés Mas and Franz Wilhelm Hopp will be ending their appointment terms and will not be up for re-election. Pilar de la Huerta and Peter Llewellyn-Davis will be nominated to replace them. De la Huerta will also resign from her position as member of the management board. Llewellyn-Davis currently serves as non-executive director and chairman of the audit committee of Shield Therapeutics. He previously served as CFO and chief business officer of MediGene.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.